"According to the Spectrem Group, which recently polled the country's wealthiest people, they're the most optimistic they've been in months," says Marc Lichtenfeld.

The contributing editor to Investment U explains, "Let's take a look at 3 stocks that millionaires (and aspiring ones) should pay attention to: Apple (AAPL), Bristol-Myers Squibb (BMY) and Varian Medical Systems (VAR).

"And according to Fidelity, 83% of millionaires surveyed said the financial crisis did not shake their confidence in investing. And of those who said they'll invest more money in the stock market, nearly 60% of them plan to buy technology stocks. And just under half expect to acquire pharmaceutical and healthcare stocks.

Analyst Upgrades

• Red Hat (RHT) and American Public (APEI) to outperform from sector perform at RBC Capital.
• KBR (KBR) and Foster Wheeler (FWLT) to buy from neutral at Goldman.
• Bio-Rad (BIO) to outperform from market perform at Leerink.
• Oceaneering (OII) to outperform from neutral at Credit Suisse.
• ASM International (ASMI) and Avid Technology (AVID) to overweight from neutral at JPMorgan.
• Dominion Resources (D) to equal weight from underweight at Morgan Stanley.
• Nationwide Health Properties (NHP) to buy from hold at Jefferies.
• Vivus (VVUS) to buy from underperform at BofA/Merrill.
• Intersil (ISIL) to buy from hold at Canaccord.

Analyst Upgrades

• Citigroup upgraded Mosaic (MOS) to buy from hold and raised its price target to $78 from $64 citing improving ag fundamentals and the potential for BHP (BHP) to issue a higher bid for Potash (POT), which Citi feels would bode well for Mosaic.
• Cowen upgraded VMware (VMW) to outperform from neutral, citing recent share weakness and the company's significant growth opportunity.
• Citigroup upgraded CareFusion (CFN) with a $29 price target, citing valuation and the potential for margin expansion.
• Pfizer (PFE) was upgraded to outperform from neutral at Cowen.
• Juniper (JNPR) was upgraded to outperform from perform at Oppenheimer.
• Stryker (SYK) was upgraded to buy from gradually accumulate at Soleil.

Analyst Upgrades

• FBR Capital upgraded Franklin Resources (BEN) to outperform from market perform and raised its target price for shares to $127 from $105 to reflect its belief the company is well positioned in the current environment.
• UBS upgraded Nuance (NUAN) to buy from neutral and has an $18 price target on the stock. The firm upgraded shares based on valuation and believes the company could be an acquisition target.
• Morgan Stanley upgraded DryShips (DRYS) to equal weight from underweight and has a $5.50 target on the stock. The firm cites the firmer ultra-deepwater drilling market for the upgrade.
• Becton Dickinson (BDX) was upgraded to neutral from sell at Goldman.
• Edwards Lifesciences (EW) was upgraded to market perform at Rodman & Renshaw.
• Arkansas Best (ABFS) was upgraded to neutral from underperform at BofA/Merrill.

"So far this year, 36 U.S.-traded stocks have declared stock splits, nearly triple the amount from all of last year," says Richard Moroney.

The editor of Dow Theory Forecasts -- an advisorty service that has focused on blue chip stocks for over 50 years -- explains, "We have reviewed stocks that have climbed to within 25% of the price of their last split. Below, we review four of these stocks, all potential stock-split candidates: Apple (AAPL), Lubrizol (LZ), TJX (TJX) and Varian Medical Systems (VAR).

"Is an increase in stock splits important? After all, stock splits have no fundamental impact on a company, neither creating nor destroying value.

Analyst Upgrades

• Weeden upgraded Nabors Industries (NBR) to buy from hold on expectations that U.S. land drillers will likely benefit from a more restrictive deepwater Gulf of Mexico drilling environment.
• Macquarie upgraded Cinemark (CNK) to outperform from neutral and has a $20 price target on the stock. The firm cites valuation, market share stabilization and Latin American pricing power.
• RBC Capital upgraded Edison International (EIX) to outperform from sector perform with a $43 target. The firm cited valuation and its belief that the company's unregulated businesses are well-positioned to accelerate as reasons for the upgrade.
• Canadian Pacific (CP) was upgraded to buy from hold at Stifel Nicolaus.
• FirstEnergy (FE) was upgraded to buy from hold at Citigroup.
• Joy Global (JOYG) was upgraded to buy from neutral at Longbow.

Analyst Upgrades

• Baird upgraded United Parcel Service (UPS) to outperform from neutral based on operating leverage, improving industry pricing and exposure to a cyclical recovery. The firm raised its target to $70 from $61.
• JMP Securities upgraded Qualcomm (QCOM) following positive wireless industry checks. The firm, which has a $60 target on the stock, believes Qualcomm is the best positioned wireless company to enable 3G deployments and the early ramp of 4G technology.
• Credit Suisse has taken a more positive stance on the potash sector given the settlement of the Chinese contracts and improving near-term fundamentals. The firm upgraded Potash (POT) to outperform from neutral and raised its price target to $135 from $119. Credit Suisse also raised Intrepid Potash (IPI) to neutral from underperform and raised its price target to $30 from $28.
• Avery Dennison (AVY) was raised to outperform from neutral at Baird.
• Biogen Idec (BIIB) was upgraded at BofA/Merrill to neutral from underperform.
• RadioShack (RSH) was upgraded to conviction buy from neutral at Goldman.

Two growth stock specialists have turned bullish on the prospects for medical equipment maker Varian Medical Systems (VAR), despite uncertainty surrounding health care legislation.

Here's a look at the company from Louis Basenese, senior analyst with The Oxford Club, along with commentary from Mark Skousen, from his specialty service, The Turnaround Alert.

Mark Skousen suggests, "One stock that should benefit from 'ObamaCare' is Varian Medical Systems, the world's leader in radiation technology and X-ray imaging.

Analyst upgrades:

• Citigroup upgraded Vistaprint (VPRT) to buy from hold on valuation following the recent pullback in shares. The firm also raised its price target on the stock to $62 from $55.
• Fox-Pitt upgraded Eaton Vance (EV) to outperform from in line citing strong fundamentals. The firm raised its target to $36 from $34.
• Stifel Nicolaus upgraded Hospitality Properties (HPT) to buy from hold citing valuation and expected cash dividend in 2010. The firm has a $22 target on the stock.
• The Advisory Board (ABCO) was upgraded to overweight from equal weight at First Analysis.
• Technip (TKPPY) was upgraded to outperform from neutral at Credit Suisse.
• Jefferies upgraded Energy XXI (EXXI) to hold from underperform and raised its target to $2 from $1.

Analyst upgrades:

• Merriman upgraded Sunpower (NASDAQ: SPWRA) two levels to Buy from Sell after transitioning coverage. The firm believes Sunpower is emerging from the current recession as the CleanTech leader and has a $38-$48 price range on shares.
• Citigroup upgraded Varian Medical (NYSE: VAR) to Buy from hold as it believes capex pressure and health care reform uncertainty is priced into shares, and demand will return as hospital budgets stabilize. Citi raised its target on shares to $45 from $36.
• FBR Capital upgraded Gap (NYSE: GPS) to Outperform from Market Perform following the Q2 results to reflect product improvement and ongoing inventory control. The firm raised its target on shares to $24 from $18.
• Schnitzer Steel (NASDAQ: SCHN) was upgraded to Neutral from Sell at UBS.
• UDR Inc. (NYSE: UDR) was upgraded to Market Perform from Underperform at Wells Fargo.
• The Buckle (NYSE: BKE) was upgraded to Buy from Hold at Roth Capital.

Analyst upgrades:

• Citigroup upgraded Adtran (NASDAQ: ADTN) to Buy from Hold on expectations the company will benefit from the broadband Stimulus funds.
• Morgan Stanley upgraded Continental Airlines (NYSE: CAL) to Overweight from Equal Weight based on relative valuation and views the company as a "survivor." Additionally, the analyst lowered 2009 industry estimates but believes it is the last cut for the year and is incrementally more positive on the sector.
• Morgan Stanley also upgraded EXFO Electro-Optical (NASDAQ: EXFO) to Overweight from Market Weight based on valuation.
• Tata Motors (NYSE: TTM) was upgraded to Buy from Hold at Deutsche Bank.
• Ascent Solar (NASDAQ: ASTI) was upgraded to Neutral from Underweight at JP Morgan.
• Mechel Steel (NYSE: MTL) was upgraded to Neutral from Underperform at Credit Suisse.

Analyst Upgrades

• Baird upgraded Starbucks (NASDAQ: SBUX) to Outperform from Neutral based on field research that indicates improving traffic trends and visibility from cost savings initiatives.
• FBR Capital upgraded E*Trade (NASDAQ: ETFC) to Outperform from Underperform citing an attractive risk/reward following the company's capital raise and debt exchange commencement. The firm believes the worst is behind the company and has a $2 target on the stock.
• Oppenheimer upgraded Sonic (NASDAQ: SONC) to Outperform from Perform on expectations demand trends will improve, leading to more normalized profitability.
• Estee Lauder (NYSE: EL) was upgraded to Equal Weight from Underweight at Barclays.
• Motorola (NYSE: MOT) was upgraded to Buy from Neutral at BofA/Merrill.
• ConAgra (NYSE: CAG) was upgraded to Buy from Neutral at UBS.

• JP Morgan upgraded shares of Amazon (NASDAQ:AMZN) to Overweight from Neutral as they believe the company's market share gains in the e-commerce sector will continue and that new product lines are adding diversification of revenue streams.
  
• Wachovia upgraded Leap Wireless (NASDAQ:LEAP) to Outperform from Market Perform citing new market launches that should drive subscriber growth and reduced ARPU deterioration.
  
• Deutsche Bank upgraded shares of Pride International (NYSE:PDE) to Buy from Hold as they believe investors will view the stock as a pure deepwater play beginning in Q2.
• PDL BioPharma (NASDAQ:PDLI) was upgraded to Neutral from Underweight at JP Morgan.
  
• Best Buy (NYSE:BBY) was raised to Buy from Neutral at Goldman.
  
• Altera (NYSE:ALTR) was upgraded at Wachovia to Outperform from Market Perform.

• Keefe Bruyette downgraded Southside Bancshares (NASDAQ:SBSI), Prosperity Bancshares (NASDAQ:PRSP), Cullen/Frost (NYSE:CFR) and BancFirst (NASDAQ:BANF) to Underperform from Market Perform on valuation and the weakening economic outlook in the Southwest.
  
• Oppenheimer cut Varian Medial (NYSE:VAR) to Perform from Outperform as they believe U.S. hospitals could reduce capital spending budgets by 15%-25% in 2009.
  
• Dress Barn (NASDAQ:DBRN) was lowered to Neutral from Buy at SunTrust based on valuation and lack of near-term catalysts.
• JetBlue (NASDAQ:JBLU) was downgraded at Jesup & Lamont to Hold from Buy.
  
• Credit Suisse cut Novellus (NASDAQ:NVLS) to Underperform from Neutral.
  
• Helen of Troy (NASDAQ:HELE) was downgraded to Underweight from Neutral at JP Morgan.

• Merriman initiated Capstone Turbine (NASDAQ:CPST) with a Neutral rating and finds the stock fairly valued at current levels.
  
• Leerink sees a high likelihood that Momenta's (NASDAQ:MNTA) lead product candidates M-Enoxaparin and M-356 clear regulatory and legal hurdles. The firm has an Outperform rating and $16 fair value estimate on shares.
  
• NCI (NASDAQ:NCIT) was initiated with a Market Perform rating at Wachovia based on valuation.
• Teradyne (NYSE:TER) was assumed at Barclays with an Overweight rating and $6 target.

Varian Medical Systems (NYSE: VAR) manufactures medical devices for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy and brachytherapy. The company also provides X-ray detectors for industrial/security applications and software for managing radiotherapy centers. The firm has manufacturing sites in North America, Europe and China and operates some 60 sales/support offices around the world.

Varian pleased investors last week, when it reported Q3 EPS of 58 cents and revenues of $513 million. Analysts had been looking for 46 cents and $480.3 million. The CEO noted that faster than expected acceptance of Varian's oncology products was a major factor leading to the successful quarter. Management also guided FY08 EPS to about $2.23 ($2.11 consensus) and FY08 revenues to about $2.08-$2.096 billion ($2.05B consensus). Needham and Lazard Capital subsequently reiterated "buy" ratings on the shares.

Monday, June 9

• The Pediatric Ethics Subcommittee of the Pediatric Advisory Committee will meet at 8:30 am to discuss the application of 21 CFR 50.52 (Clinical investigations involving greater than minimal risk but presenting the prospect of direct benefit to individual subjects) to FDA-regulated research. The discussion will be illustrated with hypothetical case examples of research involving HIV vaccines in adolescents and controlled trials of inhaled corticosteroids in children with asthma.
• Texas Instruments (NYSE: TXN) to give mid-quarter update at 5:00 pm.

Tuesday, June 10

• The Pediatric Ethics Subcommittee will meet at 8:00 am to discuss the application of 21 CFR 50.52 to FDA-regulated research illustrated with a hypothetical case example of research using stem cells for treating periventricular white matter injury in children.
• Cisco Systems (NASDAQ: CSCO) to hold conference call at 11:00 am to discuss business video innovation.
• Varian Medical Systems (NYSE: VAR) to hold mid-year review meeting at 12:00 pm.